Earlier this year, the FDA approved 2 new indications for Aquaflor. According to Merck, the supplemental approval increased ...

Merck & Co is to buy animal health firm Antelliq Group for $2.4 billion in a bid to bolster this fast-growing business unit. Antelliq, which is majority owned by private investors BC Partners ...

In the last year, many Merck & Co., Inc. ( NYSE:MRK ) insiders sold a substantial stake in the company which may ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Stronger America Through Seafood (SATS), a coalition of stakeholders in the U.S. aquaculture industry, has launched a ...

Despite challenges in GARDASIL sales, Merck & Co Inc (MRK) reports robust growth in KEYTRUDA and new product launches, ...

The Zacks Consensus Estimate for Merck’s Pharmaceutical unit is $14.96 billion, while our estimate is $14.8 billion. In the ...

With a market cap of $258 billion, Merck & Co., Inc. (MRK) is a global healthcare company, operating in the pharmaceutical and animal health sectors. Based in Rahway, New Jersey, Merck develops ...

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care ...

Animal Health grew by 6%, and KEYTRUDA sales surged by 21%. Vaccines like GARDASIL and VAXNEUVANCE experienced growth of 4% ...